MM Treatment: CAR T-Cell Therapy Selection and Insurance Considerations
The panel discusses the utilization of CAR T-cell therapy for patients with multiple myeloma, highlighting treatment selection, sequencing, and insurance considerations.
EP: 1.CAR T-Cell Therapy in Earlier Treatment Lines for Relapsed/Refractory Multiple Myeloma
EP: 2.Recent Bispecific Antibody Approvals in Relapsed/Refractory MM
EP: 3.Research on CAR T-Cell Therapy in Multiple Myeloma
EP: 4.Optimal Treatment Sequencing in Relapsed/Refractory Multiple Myeloma
EP: 5.Patient Profile: A 66-Year-Old with IgG Kappa MM
Now Viewing
EP: 6.MM Treatment: CAR T-Cell Therapy Selection and Insurance Considerations
EP: 7.Patient Profile: A 60-Year-Old with Stage III KLC MM
EP: 8.Treatment Considerations and the Role of BCMA-Targeting CAR T in MM
EP: 9.Exciting Developments in Relapsed/Refractory Multiple Myeloma
Video content above is prompted by the following questions:
- How might you consider sequencing therapies for this patient? Please describe how you would approach treating this patient in your practice.
- What factors impact your decision?
- How do you incorporate patient preferences and quality of life considerations into the discussion when determining the sequencing of bispecifics and CAR T-cell therapy in R/R MM?
- Can BCMA-targeting bispecifics be used in patients who have received prior BCMA targeting CAR-T therapies?
- Might you consider a different target?
- Might your strategy differ if the patient had received ide-cel instead of cilta-cel?
Recent Videos
![“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F70a5f0fed7009863fe30cf0740cf32014ebaf5be-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.")
Related Content
![We found that patients who are [complete remission] MRD-negative, and PET/CT negative year after year for 5 years do not have to be maintained.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fa0c5316b5733cfe8ccceb396476faf0cea2f2e46-320x410.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "We found that patients who are [complete remission] MRD-negative, and PET/CT negative year after year for 5 years do not have to be maintained.")
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025Podcast
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
